Vamsidhar Velcheti, MD
Hematology & Oncology · Jacksonville, FLNPI 1477744316
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (39.3%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 44.8% of the total. Reporting peaked in 2022 at $428,718 and has fallen 81.1% since, to $81,018 in 2025. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 390 payments — averaging $2477.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$433K
- Merck$184K
- Foundation Medicine, Inc.$69K
- AstraZeneca$43K
- Hikma Pharmaceuticals USA$38K
- Amgen$20K
- plus $178K from 36 others
Across 810 payments — averaging $8897.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2M
- Amgen$1.3M
- GSK$1.2M
- Helsinn Healthcare SA$552K
- Genentech, Inc.$481K
- Eli Lilly$459K
- plus $1.2M from 6 others
What the payments were for
- Consulting fees$361,66937%
- Speaking & faculty fees$119,21812%
- Grants$380,00039%
- Travel & lodging$92,91210%
- Food & beverage$10,3171%
- Education$1,4350%
- Charitable contribution$5690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FOUNDATIONONE CDX$68,775
- FOUNDATIONONE LIQUID$50,525
- FOUNDATIONFOCUS$50,525
- FOUNDATIONONE HEME$50,525
- FOUNDATIONONE$50,525
- LYNPARZA$47,900
- KEYTRUDA$37,507
- TAGRISSO$20,998
- LIBTAYO$16,763
- LUMAKRAS$14,028
- IMFINZI$13,572
- Ibrutinib$13,194
- Lenalidomide$13,194
- Abiraterone$13,194
- RYBREVANT$12,794
- TECENTRIQ$8,818
- ALUNBRIG$5,771
- Oncology$5,324
- OPDIVO$4,675
- ICEFX$3,933
How this compares
$966,119 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Jacksonville
- Edith PerezJacksonville$1.1M
- Arnab BasuJacksonville$440K
- Sikander AilawadhiJacksonville$179K
- James ForanJacksonville$164K
- Asher Chanan KhanJacksonville$109K
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.